This clinical study looks at how well and safe Belimumab works for adults with early Systemic Lupus Erythematosus (SLE). SLE is a disease where the immune system attacks the body by mistake. Belimumab is a medication that may help control SLE. The study lasts for 3 years and is for adults who have had SLE for less than 2 years and still have symptoms despite treatment.

Eligibility: You must have a confirmed SLE diagnosis and a positive autoantibody test. You cannot join if you have serious health problems, certain infections, or have had certain treatments recently. You also shouldn't be pregnant or breastfeeding.

Key Points:

• The study is 3 years long, and you may have several visits during this time.
• You must not have certain health conditions or infections, or be using certain medications.
• Participants must be able to give consent and manage medication through an auto-injector.